×

Chimerix falls after study disappoints

5:25 PM ET Mon, 28 Dec 2015

Biotech company Chimerix tanked more than 80% after failing to meet trial expectations for its drug that prevents infections after stem-cell transplants. CNBC’s Meg Tirrell reports the details.